National Cancer Institute NCI Cancer Bulletin: A Trusted Source for Cancer Research News
March 9, 2010 • Volume 7 / Number 5

NEWS

Miscellaneous chemotherapy bottlesExperimental Drug Benefits Patients with Advanced Prostate Cancer

The experimental drug cabazitaxel has improved the survival of some patients with advanced prostate cancer compared with those who received standard chemotherapy, according to results from a randomized phase III clinical trial presented last week at the Genitourinary Cancers Symposium in San Francisco. Although the benefit was modest (several months), there currently are no effective treatments for patients with this form of the disease, called metastatic castration-resistant, or hormone-refractory, prostate cancer. Read more > >

COMMENTARY

Director's Update: Mapping a Strategic Scientific Vision for the National Cancer Program

When we at NCI cite the National Cancer Act of 1971, it is not simply as a recitation of history, but rather a recognition of the tremendous responsibility assigned to the Institute. That legislation, which launched what is often referred to as the “War on Cancer,” imparted a series of distinctions and special authorities to NCI as the leader of the National Cancer Program. Because of the 1971 law, the position of NCI director became a presidential appointment; the outstanding and much envied NCI-designated Cancer Centers Program came into existence; and the Institute gained the authority to prepare and submit directly to the President an annual budget for review and transmittal to Congress.

The act also established a new, powerful advisory board to both the President and the NCI director: the National Cancer Advisory Board. The NCAB, the act stated, would be a presidentially appointed panel of “leading scientific or medical authorities outstanding in the study, diagnosis, or treatment of cancer or in fields related thereto.” Read more > >

  

IN DEPTH

UPDATES

  • Legislative Update

    • Congressional Hearing Focuses on the Prevention of Medical Radiation Overdoses
    • House Committee Convenes Hearing on Prostate Cancer
  • FDA Update

    • NIH-FDA Initiative Aims to Speed Development of New Medicines
    • First Meeting of FDA Tobacco Products Advisory Committee Announced
  • Cancer.gov Update

    • NCI Recovery Act Web Site Features Comparative Effectiveness Research and ACTNOW Trial Details
    • Interactive Translational Cancer Research Web Site Launched

    Notes

    • BSA Meeting Held
    • 2010 Survivorship Research Conference Accepting Applications
    • NCI and German Cancer Research Center Launch Exchange Program
    • NIH Offers New Online Health Resource for Seniors: Life after Cancer
    • NHGRI Launches Online Tool for Educators on Genetics and Genomics

Selected articles from past issues of the NCI Cancer Bulletin are available in Spanish.

The NCI Cancer Bulletin is produced by the National Cancer Institute (NCI), which was established in 1937. Through basic, clinical, and population-based biomedical research and training, NCI conducts and supports research that will lead to a future in which we can identify the environmental and genetic causes of cancer, prevent cancer before it starts, identify cancers that do develop at the earliest stage, eliminate cancers through innovative treatment interventions, and biologically control those cancers that we cannot eliminate so they become manageable, chronic diseases.

For more information about cancer, call 1-800-4-CANCER or visit http://www.cancer.gov.

NCI Cancer Bulletin staff can be reached at ncicancerbulletin@mail.nih.gov.

Next Section >